Should we be performing sentinel lymph node biopsies for HR+ patients ≥70 years of age?

Topics: Breast Cancer • Radiation Oncology • Medical Oncology • Breast Cancer, Non-metastatic

In light of updated monarchE trial data, it seems a SLNB would help delineate adjuvant treatment options in this population. However, Choosing Wisely guidelines from the Society of Surgical Oncology currently recommend against SNLB in clinically node negative women ≥ 70 years of age with early stage hormone receptor positive, HER2 negative invasive breast cancer.

What are your thoughts? Should these guidelines be updated?

Link:

https://www.choosingwisely.org/societies/society-of-surgical-oncology/

https://www.sciencedirect.com/science/article/pii/S0923753421044914?via%3Dihub

Answer from: Medical Oncologist at Academic Institution

I do not think that the monarchE data for adjuvant abemaciclib warrants changing our standard practice around omission of SLNB for patients >/= 70 yo with low-risk HR+/HER2- tumors that are clinically node-negative, because adjuvant abemaciclib is largely only appropriate for higher risk tumors a...

Comments

Medical Oncologist at Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty
This question brings up another important issue in...

Related Questions